

Neurotrope

13:29 11 Feb 2016

Thursday's followed - global share sell off and contrary Tesla

The turmoil in global equities and the oil price slide continues - with West Texas Intermediate - now hovering around the US\$27 mark - below what was called the last "psychological" cut-off of US\$30.

It is a topsy turvy world indeed currently, so no surprise perhaps then, that luxury car maker Tesla (NASDAQ:TSLA) - and Elon Musk baby - throws out another curved ball today.

Shares in the tech/ automobile firm added over 6% in New York and surged after hours after it posted quarterly earnings, which sent out a myriad of mixed fumes (although of course it didn't, cos it's electric vehicles).

On the one hand, the quarterly figures were disappointing, and less than analysts had hoped, with an adjusted loss of 87 cents per share on US\$1.75bln in sales.

But on the other there was positive news on production targets for this year and for those that follow the firm closely, exciting news that the new Model 3 vehicle will go on sale from March 31.

This is the first "moderately" priced electric car, which some may be surprised to hear has a starting price of US\$35,000.

Tesla also said it expects to ship 80,000 to 90,000 Model S and Model X cars in 2016, beating forecasts that the company would only ship about 76,000.

So what else was going on?

Junior biotech Neurotrope (OTCMKTS:NTRP) shares edged up 2.5% as it had some news on a potential treatment for devastating Alzheimer's disease.

First patients have been dosed in its phase 2b clinical trial of lead candidate Bryostatin-1 for the advanced form of the disease.

The company expects to report three month interim data during the first quarter of 2017 with complete six month data set expected during the first half of 2017.

RISERS

Tesla Motors (NASDAQ:TSLA) accelerates 6.5% to US\$152.96 after the automaker gave a forecast for deliveries of its Model X that topped analyst estimates, and also said it expected to be profitable this year.

Expedia (NASDAQ:EXPE) jumps 8.2% to US\$102.05 after giving an upbeat 2016 profit forecast.

Tripadvisor (NASDAQ:TRIP) soars 15.6% to US\$62.85 after reporting adjusted quarterly profit and revenue above

Price: US\$7

Market Cap: US\$90.46M

1 Year Share Price Graph



May 2018 November 2018 May 2019

Share Information

Code: NTRP

Listing: NASDAQ

52 week High Low
\$11.90 \$3.34

Sector: Pharma & Biotech

Website: www.neurotropebioscience.com

Company Synopsis:

Neurotrope operates as a clinical-stage biopharmaceutical and diagnostics company. Its two product platforms include a minimally-invasive diagnostic test for Alzheimer's disease and a drug candidate, known as bryostatin for the treatment of Alzheimer's disease, both of which are in the clinical testing stage.

Author:

Proactive Investors Ltd

+44 (0)207 989 0813

action@proactiveinvestors.com

estimates. It benefited from higher ad sales and an increase in subscriptions.

FALLERS

Monster Worldwide (NYSE:MWW) cascades 34% to US\$2.82 as it reported a decline in sales for its fourth quarter, which were worse than analysts had feared.

Twitter drops (NYSE:TWTR) 4.3% to US\$14.33 after the key metric of monthly average users fell, and the company gave current quarter revenue guidance that falls below Street forecasts.

SolarCity (NASDAQ:SCTY) extends Wednesdays to fall a further 7.8% to US\$17.18 after chief financial officer Brad Buss resigned, replaced by SolarCity President Tanguy Serra, in wake of poorly received 2015 earnings.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.